SELLAS Life Sciences Group, Inc. filed its Form 10-Q with the SEC on August 11, 2026, covering the quarterly period ended June 30, 2026, disclosing balance sheet figures and share count changes for the first half of the fiscal year.

Key Highlights

  • Cash and cash equivalents: $138,343 thousand as of June 30, 2026, compared to $71,793 thousand as of December 31, 2025, according to the filing.
  • Total assets: $145,382 thousand as of June 30, 2026, up from $78,345 thousand at December 31, 2025, as reported in the balance sheet.
  • Total liabilities: $7,726 thousand as of June 30, 2026, compared to $7,474 thousand at December 31, 2025.
  • Shares issued and outstanding: 201,918,874 shares as of June 30, 2026, compared to 153,103,459 shares as of December 31, 2025, per the balance sheet.
  • Authorized shares: Common stock authorized at 350,000,000 shares, $0.0001 par value, as stated in the filing.
  • Filer classification: SELLAS is classified as a non-accelerated filer and a smaller reporting company, as indicated on the cover page.

SELLAS Life Sciences Balance Sheet Shifts in the First Half of 2026

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), a Delaware-incorporated biopharmaceutical company headquartered at 7 Times Square, Suite 2503, New York, NY 10036, reported its unaudited consolidated financial statements for the quarter ended June 30, 2026. The company is focused on the development of product candidates, and the filing covers its financial condition across the six-month period ending June 30, 2026.

According to the filing, cash and cash equivalents increased to $138,343 thousand as of June 30, 2026, from $71,793 thousand reported at December 31, 2025. Total current assets rose to $142,505 thousand from $75,211 thousand over the same period. Total assets reached $145,382 thousand as of June 30, 2026, compared to $78,345 thousand at December 31, 2025. The balance sheet also reflects goodwill of $1,914 thousand at both reporting dates and operating lease right-of-use assets of $710 thousand as of June 30, 2026.

On the equity side, the company reported 201,918,874 shares of common stock issued and outstanding as of June 30, 2026, a change from 153,103,459 shares as of December 31, 2025. The filing notes that as of August 10, 2026, SELLAS had 201,945,709 shares of common stock outstanding. Total current liabilities were $7,569 thousand at June 30, 2026, and total liabilities were $7,726 thousand. The filing includes forward-looking statements, which the company states "are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially."

What Was Disclosed

SELLAS Life Sciences filed its quarterly report for the period ended June 30, 2026, disclosing balance sheet data including cash, total assets, total liabilities, and changes in shares issued and outstanding relative to December 31, 2025.